Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Yining Ye"'
Autor:
Stephen K. L. Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Sung-Bae Kim, Erik Hugger Jakobsen, Vernon Harvey, Nicholas Robert, John Smith, Graydon Harker, Bo Zhang, Lisa D. Eli, Yining Ye, Alshad S. Lalani, Marc Buyse, Arlene Chan
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disea
Externí odkaz:
https://doaj.org/article/cf5037433d854254a48613d85af66f77
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background We characterized patterns of occurrence and the impact of neratinib-associated diarrhea in the absence of protocol-directed antidiarrheal prophylaxis or a formal diarrhea management plan using data from Extended Adjuvant Treatment
Externí odkaz:
https://doaj.org/article/9fafaab688a94ee9aa6a551762b1988d
Autor:
Michael B Bass, Bin Yao, Yong-Jiang Hei, Yining Ye, Gerard J Davis, Michael T Davis, Barbara A Kaesdorf, Sabrina S Chan, Scott D Patterson
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e108048 (2014)
We sought to develop placental growth factor as a predictive pharmacodynamic biomarker for motesanib efficacy as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer.Placental growth factor was evaluated at baseline and
Externí odkaz:
https://doaj.org/article/d3ebf97e97f0499b9c74773db40ee917
Autor:
Yining Ye, Jennifer E. Arnold
Publikováno v:
Language and Linguistics Compass. 17
Publikováno v:
IEEE Transactions on Big Data. 7:81-92
Country image has a profound influence on international relations and economic development. In the worldwide outbreak of COVID-19, countries and their people display different reactions, resulting in diverse perceived images among foreign public. The
Publikováno v:
Sustainability; Volume 15; Issue 8; Pages: 6585
A steel–concrete composite box girder has good anti-seismic energy dissipation capacity, absorbs seismic energy, and reduces seismic action. It is very suitable for high-rise and super high-rise mega composite structure systems, which is in accorda
Autor:
Yining Ye
Publikováno v:
Proceedings of the 2022 2nd International Conference on Economic Development and Business Culture (ICEDBC 2022) ISBN: 9789464630350
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20af403fb6e30aeba35782ea8e4220b1
https://doi.org/10.2991/978-94-6463-036-7_171
https://doi.org/10.2991/978-94-6463-036-7_171
Publikováno v:
Findings of the Association for Computational Linguistics: ACL 2022.
Autor:
Neelima Denduluri, Marc Buyse, Robert Šeparović, Bent Ejlertsen, Stephen Chia, Gunter von Minckwitz, Alshad S. Lalani, Michael Gnant, Frankie A. Holmes, John A. Smith, Vernon Harvey, Bo Zhang, Hiroji Iwata, Janine Mansi, Beverly Moy, Sung-Bae Kim, Nicholas J. Robert, Yining Ye, Carlos H. Barrios, Erik Jakobsen, Arlene Chan, Suzette Delaloge, Miguel Martin, Lisa D. Eli, Z Tomasevic, Graydon Harker
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Chia, S K L, Martin, M, Holmes, F A, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Mansi, J, Barrios, C H, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Kim, S-B, Jakobsen, E H, Harvey, V, Robert, N, Smith, J, Harker, G, Zhang, B, Eli, L D, Ye, Y, Lalani, A S, Buyse, M & Chan, A 2019, ' PIK3CA alterations and benefit with neratinib : analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial ', Breast Cancer Research, vol. 21, 39 . https://doi.org/10.1186/s13058-019-1115-2
Breast Cancer Research : BCR
Chia, S K L, Martin, M, Holmes, F A, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Mansi, J, Barrios, C H, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Kim, S-B, Jakobsen, E H, Harvey, V, Robert, N, Smith, J, Harker, G, Zhang, B, Eli, L D, Ye, Y, Lalani, A S, Buyse, M & Chan, A 2019, ' PIK3CA alterations and benefit with neratinib : analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial ', Breast Cancer Research, vol. 21, 39 . https://doi.org/10.1186/s13058-019-1115-2
Breast Cancer Research : BCR
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free
Autor:
Gary Li, David I. Quinn, Sumanta K. Pal, Sumati Gupta, Jonathan E. Rosenberg, Yining Ye, Carl L. Dambkowski, Susan Moran, Daniel P. Petrylak, Harris S. Soifer, Dean F. Bajorin, Jean H. Hoffman-Censits, Jean Pierre Delord, Sia Daneshmand, H. A. Burris, U. De Giorgi, Matthew D. Galsky, Ulka N. Vaishampayan
Publikováno v:
European Urology Supplements. 18:e3405-e3406